Previous Article | Next Article ![]()
Journal of Clinical Microbiology, July 2001, p. 2732-2735, Vol. 39, No. 7
Conservative
Dentistry1 and Oral
Biosciences,3 Faculty of Dentistry, The
University of Hong Kong, Hong Kong, People's Republic of China, and
Division of Pharmacology, Department of Oral Medicine,
Faculty of Dental Sciences, University of Peradeniya, Peradeniya, Sri
Lanka2
There are no data on the effects of different growth media on
polyene-induced postantifungal effect (PAFE) in Candida
species. Hence, the nystatin- and amphotericin B-induced PAFEs in six
Candida species (26 isolates) grown in
Sabouraud's dextrose broth (SAB) and RPMI broth were evaluated,
following limited exposure to the MICs of the two polyenes, using an
automated turbidometric method. For nystatin, PAFE varied between 1.88 and 4.87 h in SAB and 0.66 and 6.89 h in RPMI, and for
amphotericin B, the equivalent values were 3.13 to 10.98 h in SAB and
0.97 to 7.01 h in RPMI. These highly significant
(P < 0.001) variations in the PAFE with both drugs,
noted with most Candida strains grown in different media, call for standardization of intralaboratory methodology in measuring this parameter in order to obtain universally comparable data.
Opportunistic oral infections caused
by both Candida albicans and non-C. albicans
Candida species are becoming increasingly common in
immunocompromised patients. For instance, the vast majority of
human immunodeficiency virus-infected patients suffer from oral
candidosis, the most common AIDS-associated oral infection, during the
course of their disease (1).
Nystatin and amphotericin B, which belong to the polyene group of
antimycotics, are common therapeutic agents for oropharyngeal candidosis (5). Nystatin is widely used as a topical agent in the management of oral candidosis, and oral application of this
antimycotic can also be of considerable benefit in preventing the
systemic spread of oral candidosis in immunocompromised persons (5). Though not popular, topical amphotericin B oral
preparations are available and used by some clinicians for the
management of oral candidosis (5). However, due to the
diluent effect of saliva and the cleansing effect of the oral
musculature, their availability tends to fall below the effective
therapeutic concentrations and the organisms undergo only a brief
exposure to antifungal agents (7). Hence, the term
"postantifungal effect" (PAFE) has been used in recent years to
describe the suppression of fungal growth that persists after brief
exposure of organisms to the antifungal agent in question. PAFE could
be used as a secondary benchmark in determining the antifungal activity
of an antimycotic in addition to the conventional MIC measurement. It
may also have therapeutic relevance in determining the antifungal
dosing regimens in a clinical setting (2).
There are only a few reports on the PAFE of polyene antifungal agents,
particularly with non-C. albicans Candida isolates. These
studies to determine the PAFE have essentially investigated the
interactions of a few isolates with mainly a single polyene agent
(4, 10, 11). There is also no comprehensive information on
amphotericn B-induced PAFE on different oral Candida species or the impact of growth media on the PAFE. Hence, the aim of this study
was to compare the PAFE on oral isolates of Candida
belonging to six different species following limited exposure to
nystatin and amphotericin B in two commonly used growth media, namely, Sabouraud's dextrose broth (SAB) and RPMI 1640 broth.
A total of 26 Candida isolates were studied: four isolates
each of C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, C. krusei, and C. guilliermondii, plus C. albicans ATCC 90028 and C. tropicalis ATCC 13803 used
as the reference laboratory strains. All isolates were identified using
API-20C AUX (BioMérieux, Basingstoke, United Kingdom). Stock
cultures were maintained at Nystatin and amphotericin B (both from Sigma, St. Louis, Mo.) were
dissolved in a mixture of dimethyl sulfoxide (DMSO) and absolute
ethanol (3:2 ratio), respectively. They were prepared initially as
2,000-µg/ml solutions and stored at SAB (Oxoid, Unipath Ltd, Basingstoke, Hampshire, England) was prepared
with double-distilled, sterile water. RPMI 1640 medium, buffered with
0.165 M MOPS [3-(N-morpholino)propanesulfonic acid] containing
L-glutamine and lacking sodium bicarbonate (Gibco BRL Products, Life Technology, Gaithersburg, Md.), was dissolved in 1 liter
of sterile distilled water, adjusted to pH 7.2, and filter sterilized.
MICs of nystatin and amphotericin B for each isolate were determined in
duplicate using the twofold broth microdilution technique as outlined
by the National Committee for Clinical Laboratory Standards
(9). Both RPMI 1640 and SAB were used to determine the
MIC. In brief, 10 µl of the 1 × 105- to 5 × 105-CFU/ml inoculum of the cell suspension was inoculated
into each well of a 96-well microplate containing 150 µl of medium
with a twofold-diluted concentration of the drug. The MIC was read as
the highest dilution of the drug that inhibited growth after 24 h
of incubation at 37°C in a shaking incubator (Lab-Line).
For the PAFE assay, yeast cells maintained on Sabouraud's dextrose
agar were inoculated onto fresh plates and incubated overnight prior to
use. The organisms were harvested, and a cell suspension was prepared
in 0.15 M phosphate-buffered saline (pH 7.2; PBS) to an optical density
at 520 nm of 1.5. From this cell suspension, 0.5 ml was added to tubes
containing 2 ml of medium (control) and 2 ml of medium-drug solution
(test): the drug concentration was the MIC of the drug. This gave a
cell suspension of 106 to 107 cells/ml in each
assay tube.
The control and test tubes were then incubated at 37°C for 1 h
in a shaker incubator. Following this procedure, the drug that was
carried over and contaminating the yeast cells was removed by two
cycles of centrifugation for 10 min at 3,000 rpm. The supernatant was
completely decanted, and the pellets were resuspended in 2.5 ml of
sterile PBS. This procedure has been shown to reduce the concentration
of the drug as much as 10,000-fold (2), thereby greatly
minimizing any carryover effect of the drug following its removal.
An aliquot of 100 µl from each cell suspension was added to a
microtiter well containing 150 µl of medium. Then the microtiter plate was placed in a computerized spectrophotometric incubator (Spectramax 340; Molecular Devices Corp., Sunnyvale, Calif.) and incubated at 37°C for 24 h. Plates were kept stationary on the automated reader but were automatically shaken at 30-min intervals immediately prior to the optical density readings. Growth of yeast cells was automatically monitored by the computerized instrument in
terms of the change in the turbidity (absorbance at 595 nm) at 30-min
intervals. The PAFE was determined as the difference in time (in hours)
required for the growth of the drug-free control and drug-exposed test
cultures to increase to a 0.05 absorbance level, i.e., the time
required for the turbidity of the yeast cell-suspension in the test
culture to reach the 0.05 absorbance level minus the time required for
the turbidity of the drug-free control culture to increase to the 0.05 absorbance level (3, 4, 6). In our hands the foregoing
turbidometric assessment of PAFE has proven to be highly sensitive and
reproducible (3, 6). Student's t test was used
to analyze the data.
The MICs (24 h) for all tested isolates in SAB and RPMI 1640 broth for
nystatin ranged between 1.56 and 6.25 µg/ml, while the corresponding
values for amphotericin B ranged between 0.049 and 0.78 µg/ml. These
MICs were all within the reported in vitro susceptibility values for
nystatin and amphotericin B (8), implying that all tested
isolates were susceptible to the latter polyenes.
The PAFEs of nystatin on the 26 isolates ranged between 1.88 and
4.87 h in SAB broth and 0.66 and 6.89 h in RPMI broth,
whereas equivalent figures for amphotericin B were 3.13 to 10.98 h in SAB and 0.97 to 7.01 h in RPMI broth (Table
1). These differences in the PAFE values
when yeasts were cultured in the two different media were highly
significant (P < 0.001) for both nystatin and amphotericin B, with the exception of the amphotericin B-induced PAFE
observed with C. albicans and C. glabrata in
these media (Fig. 1). A significant
interspecies variation in polyene-induced PAFE was also observed (Table
1). For instance, the mean values of amphotericin B-induced PAFE in SAB
ranged from 3.13 (for C. glabrata) to 10.98 h (for C. tropicalis).
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.7.2732-2735.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Effects of Two Different Growth Media on the
Postantifungal Effect Induced by Polyenes on Candida
Species
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
70°C. After recovery, these were
maintained on Sabouraud's dextrose agar and stored at 4 to 6°C
during the experimental period.
70°C before use. Since the
antifungal agents used were dissolved in DMSO and absolute ethanol,
equivalent amounts of the latter chemicals were tested to ascertain
whether they had an effect on the isolates tested. The minute volumes
of the chemicals used did not have any effect on yeast growth compared
with the controls.
TABLE 1.
Mean PAFE of nystatin and amphotericin B on
Candida species in SAB and RPMI 1640 broth

View larger version (38K):
[in a new window]
FIG. 1.
PAFE induced by nystatin and amphotericin B on different
Candida species growing in SAB and RPMI 1640 media. The
first bar for each species represents the PAFE induced in SAB and the
second bar represents the PAFE induced in RPMI 1640. Highly significant
(P < 0.001) variations in the PAFE values were noted,
with both nystatin and amphotericin B, when the organisms were grown in
SAB and RPMI 1640 (with the exception of amphotericin B-induced PAFE
observed in C. albicans and C. glabrata
[asterisks]).
As demonstrated previously (3, 4, 6), growth curves revealed a period of fungistasis after removal of the polyene antimycotics, illustrating a PAFE, in both SAB and RPMI 1640 medium. This was followed by a growth rate comparable to that of the unexposed controls. However, the growth rates in the two media were different, as shown by the different PAFE values (Table 1 and Fig. 1).
The incidence of oral candidosis continues to escalate, with increasing emergence of inherent or acquired resistance to antifungal agents (12), and it would be desirable if clinicians could rely on in vitro antifungal susceptibility tests to obtain critical information regarding dosage regimens. The MIC of an agent is the universally accepted criterion for evaluating dosage regimens, and the goal with respect to therapy with antimycotics is to maintain the drug concentration above the MIC throughout the dosing period (10). However, in reality, constant drug levels in the infective focus are not easily achieved, especially in the oral environment, where the salivary flushing action is constant. Therefore, additional parameters to guide and determine the dosage regimens are needed. The recently introduced concept of PAFE may serve as a further benchmark in this context together with MIC determinations.
Although a reasonable database on the PAFE of the major antifungals against a number of Candida species is available (3, 4, 6), the impact of different growth media on the PAFE of these antimycotics has not been studied. The media used in our study, namely, SAB and RPMI 1640 broth, differ in their composition and their pH. SAB contains pancreatic digest of casein, peptic digest of fresh meat, and dextrose, and its pH is 5.7 (Oxoid manual). RPMI 1640 broth is a chemically defined medium which contains a range of amino acids, vitamins, salt, and glucose, and its pH is 7.2 (Gibco BRL product guide). SAB is the recommended supporting medium for laboratory culture of fungi and has been so used for decades (2). RPMI 1640, on the other hand, was originally formulated for suspension cultures or monolayer cultures of human leukemic cells. It was subsequently recommended as the medium of choice for antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards (9). Both these media are used extensively in mycological research, especially in studies of Candida.
Our results indicate clearly that the growth patterns of the isolates in SAB and RPMI 1640 broth were variable and elicited different PAFE values depending on the medium, even with the same Candida isolate. In general, Candida growth was extensive in SAB, whereas it was comparatively low in RPMI 1640. One reason for this may be the limited nutritional sources in RPMI 1640 broth compared with SAB. Despite the differences in the media, a PAFE was observed for all isolates following brief exposure to the polyenes, and this is likely to be due to the time taken by Candida to recover before active multiplication after such exposure. Similar polyene-induced PAFE values have been observed, particularly with C. albicans, in previous studies (3, 4, 6). However, this study is the first to report the significant differences in the polyene-induced PAFE on a battery of six different Candida species in different growth media.
The present results therefore clearly illustrate that standardization of laboratory regimens is essential in order to obtain globally comparable data on PAFE of antimycotic agents. As only a few reports from a handful of laboratories on the subject of PAFE are yet available, authorities such as the NCCLS should take early steps to design and issue guidelines (akin to that for MIC measurement of antifungals) that could be universally used in evaluation of the PAFE and to generate data that are globally acceptable.
| |
ACKNOWLEDGMENTS |
|---|
These studies and A. N. B. Ellepola were supported by grants from the Research Grant Council of Hong Kong, Hong Kong, People's Republic of China.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Oral Biosciences, Faculty of Dentistry, Prince Philip Dental Hospital, 34 Hospital Rd., Hong Kong, People's Republic of China. Phone: 852-2859-0480. Fax: 852-2547-6133. E-mail: lakshman{at}hkucc.hku.hk.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Arendorf, T. M., B. Bredekamp, C. A. Cloete, and G. Sauer. 1998. Oral manifestations of HIV infection in 600 South African patients. J. Oral Pathol. Med. 27:176-179[Medline]. |
| 2. | Craig, W. A., and S. Gudmundsson. 1996. The postantibiotic effect, p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. Williams & Wilkins, Baltimore, Md. |
| 3. | Ellepola, A. N. B., and L. P. Samaranayake. 1998. The postantifungal effect (PAFE) of antimycotics on oral C. albicans isolates and its impact on candidal adhesion. Oral Dis. 4:260-267[Medline]. |
| 4. | Ellepola, A. N. B., and L. P. Samaranayake. 1999. The in vitro post-antifungal effect of nystatin on Candida species of oral origin. J. Oral Pathol. Med. 28:112-116[Medline]. |
| 5. |
Ellepola, A. N. B., and L. P. Samaranayake.
2000.
Oral candidal infections and antimycotics.
Crit. Rev. Oral Biol. Med.
11:172-198 |
| 6. | Eugusa, H., A. N. B. Ellepola, H. Nikawa, T. Hamada, and L. P. Samaranayake. 2000. Sub-therapeutic exposure to polyene antimycotics elicits a post-antifungal effect (PAFE) and depresses the cell surface hydrophobicity of oral Candida albicans isolates. J. Oral Pathol. Med. 29:206-213[CrossRef][Medline]. |
| 7. | Martin, M. V. 1990. Antifungal agents, p. 238-255. In L. P. Samaranayake, and T. W. MacFarlane (ed.), Oral candidosis. Wright, London, United Kingdom. |
| 8. | McGinnis, M. R., and M. G. Rinaldi. 1996. Antifungal drugs: mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biologic fluids, p. 176-211. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. Williams & Wilkins, Baltimore, Md. |
| 9. | National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeasts: tentative standards. NCCLS document M27-T. National Committee for Clinical Laboratory Standards, Villanova, Pa. |
| 10. | Scalarone, G. M., Y. Mikami, N. Kurita, Y. Ichihara, K. Yazawa, and M. Miyaji. 1991. Turbidometric characterization of the postantifungal effect: comparative studies with amphotericin B, 5-fluorocytosine and miconazole on Candida albicans. Mycoses 34:297-302[Medline]. |
| 11. |
Turnidge, J. D.,
S. Gudmundsson,
B. Vogelman, and W. A. Craig.
1994.
The postantibiotic effect of antifungal agents against common pathogenic yeasts.
J. Antimicrob. Chemother.
34:83-92 |
| 12. |
White, T. C.,
K. A. Marr, and R. A. Bowden.
1998.
Clinical cellular and molecular factors that contribute to antifungal drug resistance.
Clin. Microbiol. Rev.
11:382-402 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»